| Autor: |
Ntowe, Koumani W., McAdoo, Sallie, Haas, Naomi B., Karam, Jose A., Lara, Primo N., Fashoyin-Aje, Ibilola, Saraiya, Biren P., Maskens, Deborah, Pickering, Lisa, Master, Viraj A., Zhang, Tian, Kaye, Deborah R. |
| Zdroj: |
Kidney Cancer; August 2024, Vol. 8 Issue: 1 p125-134, 10p |
| Abstrakt: |
Kidney cancer is amongst the deadliest genitourinary malignancies. Neoadjuvant systemic therapy has the potential to improve survival and overall outcomes in select patients. Enrolling patients in trials of neoadjuvant treatment for kidney cancer is challenging, which limits neoadjuvant treatment development. This study aims to develop a better understanding of the barriers patients face in kidney cancer clinical trial participation, with a particular focus on neoadjuvant trials for renal cell carcinoma. From 2022–2023, we recruited participants with a history of kidney cancer through a Qualtrics survey that was sent to the Kidney Cancer Association (KCA) and Kidney Cancer Cure (KCCure) mailing lists and social media pages. Patient responses on demographics, clinical information, and perspectives were evaluated. Ninety-four individuals completed the survey. Eighty-one percent of respondents reported not participating in clinical trials due to not being informed about potential applicable trials. Importantly, many (76%) respondents reported that prevention of cancer return was a highly important reason to participate in clinical trials. Most respondents reported a willingness to undergo a kidney biopsy (59%), and/or additional appointments (58%) and surgery delays. Increased patient awareness about clinical trials with the potential to delay cancer recurrence may increase patient participation in clinical trials. Clinical trial design, including additional appointments or interventions and/or minor surgery delays are not major barriers to trial participation. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
